翰宇药业(300199) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 reached ¥133,680,763.66, an increase of 11.86% compared to the same period last year[5] - The net profit attributable to shareholders was a loss of ¥74,117,132.91, a decrease of 203.18% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥72,551,040.34, down 114.31% from the previous year[5] - The company's operating income for the first nine months of 2025 was ¥683,122,870.45, representing an 82.06% increase compared to the same period in 2024[11] - Total operating revenue for the current period reached ¥683,122,870.45, a significant increase from ¥375,225,390.50 in the previous period, representing an increase of approximately 82%[24] - Net profit for the current period was ¥69,758,073.47, compared to a net loss of ¥35,828,756.23 in the previous period, marking a turnaround in profitability[25] - The total comprehensive income for the current period was ¥68,916,881.64, compared to a loss of ¥36,542,670.37 in the previous period, indicating a significant improvement[26] Assets and Liabilities - The total assets as of September 30, 2025, amounted to ¥3,170,646,772.12, reflecting a growth of 5.40% compared to the end of the previous year[5] - The company's total assets increased to ¥3,170,646,772.12 from ¥3,008,225,640.09, reflecting a growth of approximately 5.4%[22] - Total liabilities rose to ¥2,504,569,909.28 from ¥2,411,179,128.07, an increase of about 3.9%[22] - The equity attributable to shareholders of the parent company improved to ¥649,150,598.16 from ¥578,626,837.31, showing an increase of approximately 12.2%[22] Cash Flow - The operating cash flow net amount for the year-to-date was ¥270,699,175.19, an increase of 207.37% year-on-year[5] - Operating cash inflow for the current period reached ¥799,866,415.70, a significant increase from ¥501,843,341.73 in the previous period, representing a growth of approximately 58.9%[27] - Net cash flow from operating activities was ¥270,699,175.19, compared to ¥88,069,613.03 in the prior period, indicating a year-over-year increase of 207.5%[27] - The net increase in cash and cash equivalents for the current period was ¥24,473,569.69, contrasting with a decrease of -¥204,507,285.80 in the previous period[28] - The ending balance of cash and cash equivalents stood at ¥117,006,412.85, compared to ¥135,428,940.64 at the end of the previous period[28] Investments and Shareholder Information - The investment income for the first nine months of 2025 was ¥2,723,249.93, a significant increase of 614.25% year-on-year[12] - The company reported an investment income of ¥2,723,249.93, a recovery from a loss of ¥529,557.23 in the previous period[25] - The total number of common shareholders at the end of the reporting period is 110,118[15] - The largest shareholder, Zeng Shaogui, holds 11.16% of shares, amounting to 98,533,635 shares, with 41,190,000 shares pledged[15] - The top ten shareholders collectively hold significant stakes, with the top three being brothers and controlling shareholders of the company[16] Research and Development - Research and development expenses for the current period were ¥74,125,204.88, up from ¥59,329,000.15, indicating a growth of about 25%[24] Operational Changes and Approvals - The company signed a series of agreements with Sanofi on August 20, 2025, marking a new phase in the commercialization of their product[17] - The company received marketing approval for Acetate Atosiban Injection in Vietnam on August 22, 2025, expanding its overseas product pipeline[18] - The company and DS3 RX LLC mutually agreed to terminate their cooperation agreement, ending all unfulfilled obligations[18] Inventory and Current Assets - Total current assets rose to ¥565,088,980.79 from ¥463,048,006.84, indicating an increase of about 22.0%[20] - Inventory increased to ¥288,158,914.76 from ¥238,630,347.88, reflecting a growth of approximately 20.9%[20] Cash Flow from Activities - Cash outflow from investment activities totaled ¥173,272,458.81, up from ¥74,866,778.32, resulting in a net cash flow from investment activities of -¥165,492,033.13, worsening from -¥28,726,078.08[28] - Cash inflow from financing activities was ¥1,107,100,971.04, down from ¥1,241,333,185.23, while cash outflow from financing activities was ¥1,189,769,767.06, compared to ¥1,507,182,727.29 in the previous period[28] - The net cash flow from financing activities improved to -¥82,668,796.02 from -¥265,849,542.06, showing a reduction in cash outflow[28] Tax and Other Income - The company received ¥24,529,820.17 in tax refunds, significantly higher than ¥6,169,638.15 in the prior period, marking an increase of approximately 297.5%[27] - The company reported cash inflow from other operating activities of ¥133,946,814.91, up from ¥55,534,396.69, reflecting an increase of about 141.5%[27] - The company’s cash inflow from investment income was ¥3,288,131.02, a notable increase from ¥614,700.24 in the previous period[27]